Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer
Guo‐fu Hu, Nan He, Chuanqi Cai, et al.
Pancreatology (2019) Vol. 19, Iss. 2, pp. 383-389
Closed Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Regulatory mechanisms of PD-1/PD-L1 in cancers
Xin Lin, Kuan Kang, Pan Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 111
Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer.
Shunda Wang, Yatong Li, Xing Cheng, et al.
PubMed (2020) Vol. 10, Iss. 7, pp. 1937-1953
Closed Access | Times Cited: 93
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
Katrin Pansy, Barbara Uhl, Jelena Krstić, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13311-13311
Open Access | Times Cited: 82
Role of STAT3 in pancreatic cancer
Zachary Hamel, S. Calabrese Sánchez, David Standing, et al.
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 1, pp. 20-33
Open Access | Times Cited: 8
Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
Zhijie Wang, L. Yuan, Xiaotong Liao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6027-6043
Closed Access | Times Cited: 8
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy
Nilanjan Adhikari, Tarun Jha, Balaram Ghosh
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 13, pp. 8827-8869
Closed Access | Times Cited: 46
Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert
Xiaoqi Li, Mansi Gulati, Alaina C. Larson, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 14-27
Open Access | Times Cited: 34
HDAC3 inhibition promotes anti-tumor immunity by enhancing CXCL10 mediated chemotaxis and recruiting of immune cells
Lili Li, Shumin Hao, Meiling Gao, et al.
Cancer Immunology Research (2023) Vol. 11, Iss. 5, pp. 657-673
Open Access | Times Cited: 21
Discovery of Novel HDAC3 Inhibitors with PD-L1 Downregulating/Degrading and Antitumor Immune Effects
Zhiqiang Sun, Chenglong Xu, Jinmei Cheng, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 15, pp. 13067-13088
Closed Access | Times Cited: 6
KDELR2 promotes breast cancer proliferation via HDAC3‐mediated cell cycle progression
Haoran Wei, Wenhao Ma, Xiaofei Lü, et al.
Cancer Communications (2021) Vol. 41, Iss. 9, pp. 904-920
Open Access | Times Cited: 39
Contemporary clinical trials in pancreatic cancer immunotherapy targeting PD-1 and PD-L1
Ganji Purnachandra Nagaraju, Rama Rao Malla, Riyaz Basha, et al.
Seminars in Cancer Biology (2021) Vol. 86, pp. 616-621
Closed Access | Times Cited: 38
Emerging role of PD-L1 modification in cancer immunotherapy.
Xiaoli Hu, Zixia Lin, Zhiwei Wang, et al.
American Journal of Cancer Research (2021) Vol. 11, Iss. 8, pp. 3832-3840
Closed Access | Times Cited: 33
CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression
Huifeng Gao, Chien‐shan Cheng, Jian Tang, et al.
Aging (2020) Vol. 12, Iss. 1, pp. 502-517
Open Access | Times Cited: 36
Discovery of Novel Hydrazide-Based HDAC3 Inhibitors as Epigenetic Immunomodulators for Cancer Immunotherapy
Zhiqiang Sun, Jinmei Cheng, Chenglong Xu, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Discovery of Highly Potent and Orally Bioavailable Histone Deacetylase 3 Inhibitors as Immunomodulators and Enhancers of DNA-Damage Response in Cancer Therapy
Shuqing Li, Zhihao Hu, Wanyi Pan, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
HDAC3: A Multifaceted Modulator in Immunotherapy Sensitization
Rui Han, Yi‐Bo Luo, Jingdong Gao, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 182-182
Open Access
The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance
Javier Martínez‐Useros, Mario Martin-Galan, Jesús García‐Foncillas
Cancers (2021) Vol. 13, Iss. 2, pp. 322-322
Open Access | Times Cited: 26
Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer
Xuesong Xiang, Pengcheng Li, Wenquan Wang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 1, pp. 188676-188676
Closed Access | Times Cited: 18
Role of Epigenetics in Pancreatic Ductal Adenocarcinoma
Somnath Pandey, Vineet K. Gupta, Shweta Lavania
Epigenomics (2023) Vol. 15, Iss. 2, pp. 89-110
Open Access | Times Cited: 10
Structure-based screening of FDA-approved drugs identifies potential histone deacetylase 3 repurposed inhibitor: molecular docking and molecular dynamic simulation approaches
Anas Shamsi, Mohd Shahnawaz Khan, Dharmendra Kumar Yadav, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases
Wynne Sim, Wei‐Meng Lim, Ling‐Wei Hii, et al.
World Journal of Gastroenterology (2022) Vol. 28, Iss. 18, pp. 1934-1945
Open Access | Times Cited: 15
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?
Clemens Zwergel, Rossella Fioravanti, Antonello Mai
Drug Discovery Today (2022) Vol. 28, Iss. 2, pp. 103435-103435
Closed Access | Times Cited: 15
Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model
Ganesh Routholla, Sravani Pulya, Tarun Patel, et al.
Bioorganic Chemistry (2021) Vol. 117, pp. 105446-105446
Closed Access | Times Cited: 19
GNG12 regulates PD‐L1 expression by activating NF‐κB signaling in pancreatic ductal adenocarcinoma
Juan Li, Can Jin, Chuanxin Zou, et al.
FEBS Open Bio (2020) Vol. 10, Iss. 2, pp. 278-287
Open Access | Times Cited: 20
Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review)
Xiaoran Ma, Jibiao Wu, Bin Wang, et al.
International Journal of Oncology (2022) Vol. 61, Iss. 5
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top